Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2019 - 2025)

Cumberland Pharmaceuticals' Gains from Investment Securities history spans 9 years, with the latest figure at -$96754.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 110.17% year-over-year to -$96754.0; the TTM value through Dec 2025 reached -$3525.0, down 123.5%, while the annual FY2025 figure was -$3525.0, 123.5% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$96754.0 at Cumberland Pharmaceuticals, down from $9651.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $951072.0 in Q4 2024 and bottomed at -$1.0 million in Q4 2022.
  • The 5-year median for Gains from Investment Securities is -$211891.0 (2024), against an average of -$144311.7.
  • The largest annual shift saw Gains from Investment Securities plummeted 263.9% in 2022 before it skyrocketed 119.52% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $632319.0 in 2021, then tumbled by 263.9% to -$1.0 million in 2022, then surged by 74.18% to -$267637.0 in 2023, then surged by 455.36% to $951072.0 in 2024, then plummeted by 110.17% to -$96754.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Gains from Investment Securities are -$96754.0 (Q4 2025), $9651.0 (Q3 2025), and $38602.0 (Q2 2025).